All the top Biotech & Pharma news in one daily newsletter.

Want to understand how these updates are formatted? Check-out the FAQ.

Have any feedback? I’d love to hear you from - connect with me on LinkedIn. 📣

Looking to reach an audience of 1800+ biotech and pharma professionals? Let’s chat. 👍

THE GOOD
Approvals & Labels

Johnson & Johnson's Tremfya (targeting IL-32) receives FDA approval for moderately to severely active Crohn's disease in adults
Monoclonal antibody, Crohn's disease - Read more

Novartis' Fabhalta (targeting C3) approved by FDA to reduce proteinuria in C3 glomerulopathy, a rare kidney disease
Small molecule, C3 glomerulopathy - Read more

PathAI's AI tool, AIM-NASH, received European qualification for analyzing liver biopsies to determine metabolic dysfunction-associated steatohepatitis severity in clinical trials
Metabolic dysfunction-associated steatohepatitis (MASH), AI, drug development, biopsy analysis - Read more

Glenmark receives FDA approval for Olopatadine Hydrochloride, a histamine blocker for allergic conjunctivitis, as over-the-counter eye drops
Small molecule, infectious conjunctivitis - Read more

PRESENTED BY YOU?
Get the attention of 1800+ Biotech & Pharma Professionals 🤩

Do you offer a biotech/pharma-focused product or service?

Or looking to get investor/analyst interest on your budding start-up?

Considering sponsoring TLDR Biotech to get in-front of an engaged audience of biotech & pharma-focused professionals.

Just reply to this email* or message me on LinkedIn to learn more.

*If you’re reading this on the web version, email [email protected]

⬇️ More Good News ⬇️

THE GOOD
Clinical Trials

Akeso's cadonilimab, a PD-1/CTLA-4 bispecific antibody, plus chemoradiotherapy shows promising Ph3 results for locally advanced cervical cancer
Bispecific antibody, cervical cancer - Read more

Johnson & Johnson's Rybrevant (targeting EGFR, MET) plus Lazcluze (targeting EGFR) improves survival in Ph3 trial for EGFR-mutated non-small cell lung cancer compared to osimertinib (targeting EGFR)
Bispecific antibody, small molecule, lung cancer - Read more

THE GOOD
Fundraises

Andreessen Horowitz plans a $750M Bio Fund to back next-gen life-science and healthcare startups; fund is half previous size
Venture capital, biotech investing, life science investment - Read more

GENFIT nabs $141M royalty financing from HealthCare Royalty, funding liver disease and acute-on-chronic liver failure pipeline development.
Royalty, small molecule, liver disease - Read more

LigaChem Bio invests $25M in partner Iksuda Therapeutics, to accelerate ADC pipeline clinical development and gain management control
Antibody-drug conjugate (ADC), cancer, drug development - Read more

THE GOOD
Investments

AstraZeneca pledges $2.5B investment in Beijing for drug research and manufacturing over five years, including AI lab development
New facility, facility expansion, manufacturing, research & development, AI, data science - Read more

Johnson & Johnson to invest $55 billion over four years in US manufacturing, R&D, and technology, including new North Carolina facility
Domestic manufacturing, research & development, new facility, facility expansion - Read more

OmniaBio expands Hamilton facility with federal support to enhance cell and gene therapy production using AI and robotics
Cell therapy, cell therapy manufacturing, gene therapy, gene therapy manufacturing, AI, facility expansion - Read more

THE GOOD
Partnerships

AstraZeneca, Harbour BioMed sign global collab to develop multi-specific antibodies for immunology and oncology with $105M equity investment
Multispecific antibody, drug discovery, drug development, cancer - Read more

AstraZeneca, Syneron Bio partner to develop macrocyclic peptides for chronic diseases leveraging Syneron's Synova platform
Peptide, chronic disease, drug development - Read more

Grifols, Inpeco partner to modernize transfusion medicine labs with automation and diagnostic solutions
Equipment/Instrumentation, software, laboratory automation - Read more

THE GOOD
Patient Access

Canada signs $9.5 million pharmacare agreement with Yukon territory to provide free contraceptive and diabetes medications by 2026
Drug access, diabetes, contraceptive access - Read more

Canada signs $39 million agreement with province of Nova Scotia to improve access to rare disease drugs and diagnostics
Drug access, rare disease - Read more

Optum Rx shifting to cost-based pharmacy payment model by 2028 to address drug pricing challenges for independent pharmacies
Pharmacy, reimbursement - Read more

THE GOOD
Politics & Policy

European countries, including the Netherlands, create initiatives to attract US researchers amid research funding cuts in the United States
Talent acquisition - Read more

THE GOOD
Product Launches

VantAI launches Neo-1 AI system for drug discovery, combining prediction and generation abilities, already used by major pharmaceutical companies
Drug discovery, AI - Read more

THE GOOD
Research

Poxel's PXL065 (targeting PPARγ) shows promising results in reducing hypertrophy and fibrosis in preclinical hypertrophic cardiomyopathy study
Small molecule, hypertrophic cardiomyopathy - Read more

Study finds single Imvanex dose protects against Mpox with 84% effectiveness, but two doses needed for HIV patients.
Vaccine, Mpox (monkeypox), human immunodeficiency virus (HIV) - Read more

THE GOOD
Strategic Plans

BlissBio to trudges on with BB-1701 (targeting HER2) development despite Eisai declining licensing option
Antibody-drug conjugate (ADC), breast cancer, solid tumor, pipeline strategy - Read more

PRESENTED BY TLDR BIOTECH
What would you do with 6.5k+ meticulously tagged biotech & pharma data points?
*New* Sample Data Available - See below!

Over the past year, TLDR Biotech has been collecting and categorizing industry news across approvals, clinical trials, fundraises, partnerships, M&A, politics & policy, and much much more.

Each data point is tagged by drug modality, disease indication, tech area, and even more specific categories. For example:

🔍 Need to track all small molecule fundraises across oncology?

📈 Want a curated list of recent cell therapy clinical trials updates (both the successes and failures)?

💡 Looking for trends in Alzheimer's and Parkinson's disease partnerships?

Here’s a sample set of data - lung cancer stories over the last 3 months.

If you’re interested, send us an email [email protected] with the subject line “6K BIOTECH DATA” and we’ll chat further.*

*If you’ve received this newsletter as an email, just hit reply!

THE BAD
Approvals & Labels

FDA hands Hengrui Pharmaceuticals and Elevar Therapeutics a complete response letter (CRL) for camrelizumab (PD-1 inhibitor) and rivoceranib (VEGFR inhibitor) combination for first-line liver cancer treatment due to manufacturing issues
Monoclonal antibody, small molecule, liver cancer - Read more

THE BAD
Business Development

Pulmatrix selling pipeline programs and iSPERSE technology before merger with Cullgen, now closing in 2025
Small molecule, migraine, chronic obstructive pulmonary disease (COPD), antifungal, drug delivery - Read more

THE BAD
Earnings & Finances

Alnylam prices heart drug Amvuttra at nearly double the cost of competitors, citing “superior value”
siRNA, transthyretin amyloidosis/transthyretin amyloid cardiomyopathy (ATTR-CM) - Read more

THE BAD
Layoffs

Vaxart lays off 10% after US government orders halt to COVID vaccine pill trial comparing it to mRNA vaccines
Vaccine, COVID-19, US Department of Health & Human Services (HHS) - Read more

THE BAD
Politics & Policy

Trump think tank proposes resurrecting international drug pricing policy to combat foreign "freeloading" on US pharmaceutical innovation
Drug pricing - Read more [Paywall]

BARDA cancels June industry-government biomedical event amid Trump administration scrutiny of its pandemic response initiatives
Biomedical Advanced Research and Development Authority (BARDA) - Read more [Paywall]

THE BAD
Strategic Plans

MacroGenics discontinues vobramitamab duocarmazine (targeting B7-H3) development after patient deaths and poor results in prostate cancer trial
Antibody-drug conjugate (ADC), prostate cancer, pipeline strategy - Read more

THE UGLY
Layoffs

HHS healthcare quality research agency faces potential 80-90% staff cuts under Trump administration's downsizing efforts.
US Department of Health & Human Services (HHS) - Read more [Paywall]

You’re all caught up on the latest Pharma & Biotech News!

TLDR Biotech wants to hear from you! 📣

Have comments/questions/complaints about this newsletter?
Send me an email - I want your brutally honest feedback. 📝

Last thing - if you find the content useful and think a colleague would too, please share TLDR Biotech with them! ♻️

Disclaimer: Content, news, research, tools, and mention of stock or tradeable securities are for educational and illustrative purposes only and do not imply a recommendation or solicitation to buy or sell a particular security or to engage in any particular investment strategy. Read the full terms & conditions here